Is safe endoscopic submucosal dissection of superficial spreading early gastric cancer?

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

YongSeok Kang

Citation

Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523

Authors

Y. Kang1, K. Lee2, H. Kim2

Author affiliations

  • 1 Internal Medicine, Yonsei University Wonju College of Medicine, 220-701 - Wonju/KR
  • 2 Internal Medicine, Yonsei University Wonju College of Medicine, Wonju/KR
More

Resources

Aim/Background

Endoscopic submucosal dissection is an alternative modality of surgery in treatment of early gastric cancer (EGC). The size of EGC is not a limitation of endoscopic treatment, but there are few data on prosperity of endoscopic treatment of superficial spreading EGC. The aim of this study was to investigate the rate and risk factors of lymph node metastasis of superficial spreading EGC for establishing proper criteria of endoscopic treatment of superficial spreading EGC.

Methods

Between 2000 and 2010, the patients who received curative surgery due to early gastric cancer in Severance Hospital, Seoul, Korea were enrolled. Superficial spreading EGC was defined as the largest lesion ≥6 cm.

Results

Of 2758 EGC lesions, 105 (3.8%) lesions had a size of ≥6 cm, and 2653 (96.2%) lesions had a size of <6 cm.Superficial spreading EGC had higher rate of submucosal cancer 60.0% vs. 46.1%, P = 0.005) and lymphovascular invasion (25.7% vs. 12.7%, P < 0.0001) than <6 cm EGC. In the multivariable analysis, the odd ratio of tumor size (≥ 6 cm) was 1.28 (95% confidence interval, P = 0.388) for lymph node metastasis without statistical significance. In 105 patients with tumor size (≥ 6 cm), the rate of lymph node metastasis was higher in submucosal cancer than in mucosal cancer (25.4% vs. 7.1%, P = 0.017). The lymph node metastasis was significantly associated with lymphovascular invasion.

Conclusions

Superficial spreading EGC was not associated with an increased risk of lymph node metastasis as compared to EGC <6 cm.This finding suggests that superficial spreading EGC become a candidate of endoscopic treatment as EGC with smaller size.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings